^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG7356

    i
    Other names: RO5429083, RG-7356, RO-5429083, RG7356, RG 7356
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD44 inhibitor
    Associations

    News

    Trials
    almost6years
    CD44v6 engages in colorectal cancer progression. (PubMed, Cell Death Dis)
    Moreover, clinical trials aiming to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and toxicity of a commercialized anti-CD44 monoclonal antibody developed by Roche (RO5429083) have been conducted among patients with CD44-expressing malignant tumors, and a clinical trial focusing on the dose escalation of this antibody is ongoing. Thus, we are hopeful that anti-CD44 therapy will be applied in the treatment of colorectal cancer in the future.
    Review • Journal
    |
    VEGFA (Vascular endothelial growth factor A) • HGF (Hepatocyte growth factor) • CD44 (CD44 Molecule) • EGF (Epidermal growth factor)
    |
    RG7356